RELATED CONTENT
July 25, 2012 — Positron Corp. announced approval of a pledge for $15 million in tax increment financing (TIF) bonds from the redevelopment commission of the city of Gary, Ind., toward the development of Positron's 70 MeV cyclotron project.
July 25, 2012 
June 13, 2012 — Positron Corp. announced completion of its first strontium validation effort in May 2012, when Manhattan Isotope Technology (MIT), a Positron subsidiary, successfully processed strontium.
June 13, 2012 April 6, 2012 — Positron Corp. announced the approval of its Nuclear Regulatory Commission (NRC) manufacturing and distribution license amendment for the company's radiopharmaceutical manufacturing facility in Crown Point, Ind.
April 06, 2012 February 24, 2012 — Positron Corp., through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT), announced it had received its first shipment of strontium-82 (Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France.
February 24, 2012 
January 30, 2012 — Positron Corp., a molecular imaging healthcare company specializing in the field of nuclear cardiology, announced Jan. 23 that its wholly owned subsidiary, Manhattan Isotope Technology (MIT), received approval for its radioactive materials license amendment. The Texas Department of State Health Services -- Radiation Control Program granted the amendment approval.
January 30, 2012 January 20, 2012 – Nuclear cardiology imaging company Positron Corp. this week acquired Manhattan Isotope Technology LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.
January 20, 2012 
December 16, 2011 — Positron Corp. announced this week that on Dec. 12, 2011, its Attrius & Attrius L positron emission tomography (PET) scanners received approval for sale in Canada.
December 16, 2011 Despite its first commercial appearance in the late 1970s, positron emission tomograpnhy (PET) did not begin gaining widespread acceptance as a viable clinical technology until the mid-1990s. This was after it gained approval for reimbursement and radiopharmaceuticals for PET became more widely available.
July 18, 2011 
July 16, 2010 – High demand has led Positron Corp. to increase production of Attrius positron emission tomography (PET) scanner with its joint venture, Neusoft Positron Medical Systems, the company announced recently.
July 16, 2010 
November 12, 2009 - Positron Corp. predicts an industry wide demand for cardiac PET imaging, as a result of the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule increasing Cardiac PET reimbursement by 20 percent, while reducing coverage for SPECT by 36 percent.
November 12, 2009